PLAINSBORO, N.J., Oct. 5, 2010 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) will offer four workshops at the 65th Annual Meeting of the American Society for Surgery of the Hand (ASSH) on October 7-9 in Boston, Massachusetts. Almost 400 surgeons have signed up for the workshops, which will focus on wrist arthritis, nerve repair, ulnar nerve decompression, and radial head fractures.
The conference is expected to attract over 2,275 general, orthopedic and plastic hand surgeons, as well as several hundred executives from the small bone and joint market. The convention includes over 100 manufacturer and service provider booths.
"Integra is proud to participate at the ASSH meeting as a Premier Partner," said Robert Paltridge, President of Integra Extremity Reconstruction. "Our products offer solutions for many of the surgical procedures discussed at ASSH, and we're pleased that we can give surgeons the opportunity to participate in our workshops and gain valuable insight into the use of our products."
Integra's exhibit (booth #209) will also highlight other products, including the newly released IntegraTM Total Wrist Fusion System, Inforce® Reinforcement Matrix, and EndoRelease™ Endoscopic Cubital Tunnel Release System.
Schedule of Integra sponsored ASSH Workshops:
This workshop will feature a presentation of published literature and outcomes for endoscopic cubital tunnel release. In addition, an examination of the clinical history of the procedure, including the indications, contraindications and complications, will be discussed. Faculty will review the surgical technique and benefits of performing an endoscopic release with the leading EndoReleaseTM Endoscopic Cubital Tunnel System.
This workshop will examine clinical history and outcomes for radial head fracture repair and elbow reconstruction. Along with this didactic portion, the workshop will also include a demonstration of the latest surgical technique for performing radial head reconstruction with the KatalystTM Bipolar Radial Head System.
This workshop will focus on advanced wrist arthritis and present the newest technologies for treatment. By using a variety of techniques and implants, a surgeon can better match treatment to the patient's type of arthritis, physical demands, and desires. Among the techniques to be presented will be the newly released IntegraTM Total Wrist Fusion System featuring reduced distal tip profile and Surfix® locking technology and the leading Universal2TM Total Wrist Implant System used in various configurations for non-rheumatoid patients.
This workshop will focus on the application of new collagen technology for management of complex acute and chronic peripheral nerve problems in a case discussion format. Treatment of nerve injuries and management of scarred nerves after trauma is challenging. Collagen wraps and conduits provide an innovative way to approach these cases. Complex clinical cases will be presented and various options discussed with interactive participation from the audience.
Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery. For more information, please visit
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of Integra products. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2009 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences Holdings Corporation Gianna Sabella, Director, Corporate Communications (609) 936-2389 email@example.com